Together with our partner Brain Research Center, we presented the webinar:

 Innovative Endpoints in Alzheimer’s Disease Clinical trials.

During this webinar, two experts in the field, Dr. Niels Prins and Dr. Jort Vijverberg discussed the latest clinical and biomarker endpoints.

During this webinar our experts expanded on how we advance clinical drug development for Alzheimer’s disease by touching upon:
> Biomarker-based participant selection;
> inclusion criteria for upcoming AD trials
> Fluid biomarkers as endpoints in your AD trial;
> EEG; a ‘novel’ AD biomarker.